Age at onset determines severity and choice of treatment in early rheumatoid arthritis: A prospective study

Arthritis Research and Therapy

Volumn 16, Issue 2, 2014, Pages

  Innala, Lena ^a   Berglin, Ewa ^a   Möller, Bozena ^a   Ljung, Lotta ^a   Smedby, Torgny ^a   Södergren, Anna ^a   Magnusson, Staffan ^a   Rantapää Dahlqvist, Solbritt ^a   Wållberg Jonsson, Solveig ^a,b  

^a UMEÅ UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EPITOPE; LEUKOCYTE ANTIBODY; METHOTREXATE; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR; ANTIRHEUMATIC AGENT; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE NONRECEPTOR TYPE 22; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE EROSION; COMORBIDITY; CORTICOSTEROID THERAPY; DAS28; DISEASE ACTIVITY; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOOT RADIOGRAPHY; GENETIC VARIABILITY; HAND RADIOGRAPHY; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN ANALYSIS; RHEUMATOID ARTHRITIS; RISK FACTOR; TREATMENT PLANNING; VISUAL ANALOG SCALE; ADOLESCENT; ARTHRITIS, RHEUMATOID; MIDDLE AGED; PATHOPHYSIOLOGY; REGISTER; VERY ELDERLY; YOUNG ADULT; CARDIOVASCULAR DISEASE; DISEASE COURSE; DRUG THERAPY; FOLLOW UP; GENETIC MARKER; SWEDEN;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; MIDDLE AGED; REGISTRIES; YOUNG ADULT;

EID: 84901595666     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4540     Document Type: Article

References (55)

1. Rasch EK, Hirsch R, Paulose-Ram R, Hochberg MC. Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum 2003, 48:917-926. 10.1002/art.10897, 12687533.
2. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984, 27:864-872. 10.1002/art.1780270805, 6431998.
3. van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, van der Veen MJ, Haanen HC, Hofman DM, van Albada-Kuipers GA, ter Borg EJ, Brus HL, Dinant HJ, Kruize AA, Schenk Y. The effectiveness of early treatment with " second-line" antirheumatic drugs: a randomized, controlled trial. Ann Intern Med 1996, 124:699-707. 10.7326/0003-4819-124-8-199604150-00001, 8633829.
4. Wallberg Jonsson S, Ohman ML, Rantapää-Dahlqvist S. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in northern Sweden. J Rheumatol 1997, 24:445-451.
5. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008, 26:S35-S61.
6. Sokka T, Mäkinen H. Drug management of early rheumatoid arthritis-2008. Best Pract Res Clin Rheumatol 2009, 23:93-102. 10.1016/j.berh.2008.08.003, 19233049.
7. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008, 59:1690-1697. 10.1002/art.24092, 19035419.
8. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010, 376:1094-1108. 10.1016/S0140-6736(10)60826-4, 20870100.
9. Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, Rantapää-Dahlqvist S. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 2006, 65:453-458. 10.1136/ard.2005.041376, 1798112, 16176994.
10. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, Saigo K, Morinobu A, Koshiba M, Kuntz KM, Kamae I, Kumagai S. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007, 146:797-808. 10.7326/0003-4819-146-11-200706050-00008, 17548411.
11. Pease CT, Bhakta BB, Devlin J, Emery P. Does the age of onset of rheumatoid arthritis influence phenotype? A prospective study of outcome and prognostic factors. Rheumatology (Oxford) 1999, 38:228-234. 10.1093/rheumatology/38.3.228, 10325661.
12. Calvo-Alén J, Corrales A, Sánchez-Andrada S, Fernández-Echevarría MA, Peña JL, Rodríguez-Valverde V. Outcome of late-onset rheumatoid arthritis. Clin Rheumatol 2005, 24:485-489. 10.1007/s10067-004-1067-4, 15750680.
13. Tutuncu Z, Reed G, Kremer J, Kavanaugh A. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment?. Ann Rheum Dis 2006, 65:1226-1229. 10.1136/ard.2005.051144, 1798297, 16414968.
14. Bukhari M, Lunt M, Barton A, Bunn D, Silman A, Symmons D. Increasing age at symptom onset is associated with worse radiological damage at presentation in patients with early inflammatory polyarthritis. Ann Rheum Dis 2007, 66:389-393. 10.1136/ard.2006.055657, 1855997, 16950810.
15. Radovits BJ, Fransen J, Eijsbouts A, van Riel PL, Laan RF. Missed opportunities in the treatment of elderly patients with rheumatoid arthritis. Rheumatology (Oxford) 2009, 48:906-910. 10.1093/rheumatology/kep129, 19478038.
16. Oka M, Kytila J. Rheumatoid arthritis with the onset in old age. Acta Rheumatol Scand 1957, 3:249-258.
17. Adler E. Rheumatoid arthritis in old age. Isr J Med Sci 1966, 2:607-613.
18. Ehrlich GE, Katz WA, Cohen SH. Rheumatoid arthritis in the aged. Geriatrics 1970, 25:103-113.
19. Corrigan AB, Robinson RG, Terenty TR, Dick-Smith JB, Walters D. Benign rheumatoid arthritis of the aged. Br Med J 1974, 1:444-446. 10.1136/bmj.1.5905.444, 1633225, 4131601.
20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
21. Ferraccioli GF, Cavalieri F, Mercadanti M, Conti G, Viviano P, Ambanelli U. Clinical features, scintiscan characteristics and X-ray progression of late onset rheumatoid arthritis. Clin Exp Rheumatol 1984, 2:157-161.
22. van der Heijde DM, van Riel PL, van Leeuwen MA, van 't Hof MA, van Rijswijk MH, van de Putte LB. Older versus younger onset rheumatoid arthritis: results at onset and after 2 years of a prospective followup study of early rheumatoid arthritis. J Rheumatol 1991, 18:1285-1289.
23. Kremers HM, Nicola P, Crowson CS, O'Fallon WM, Gabriel SE. Therapeutic strategies in rheumatoid arthritis over a 40-year period. J Rheumatol 2004, 31:2366-2373.
24. Fraenkel L, Rabidou N, Dhar R. Are rheumatologists' treatment decisions influenced by patients' age?. Rheumatology (Oxford) 2006, 45:1555-1557. 10.1093/rheumatology/kel144, 1660557, 16690762.
25. Schmajuk G, Schneeweiss S, Katz JN, Weinblatt ME, Setoguchi S, Avorn J, Levin R, Solomon DH. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum 2007, 57:928-934. 10.1002/art.22890, 17665462.
26. Baecklund E, d'Elia HF, Turesson C. Svensk Reumatologisk Förening: Riktlinjer för Läkemedelsbehandling vid Reumatoid Artrit [120419] 2012, Göteborg, Sweden: Svensk Reumatologisk Förening, Available at http://www.svenskreumatologi.se/riktlinjer (accessed 20 April 2014).
27. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975. 10.1136/ard.2009.126532, 2935329, 20444750.
28. Singh JA, Saag KG, Furst D. Reply to letter by Graudal and Jürgens. Arthritis Care Res (Hoboken) 2013, 65:832-833.
29. Möttönen T, Hannonen P, Korpela M, Nissilä M, Kautiainen H, Ilonen J, Laasonen L, Kaipiainen-Seppänen O, Franzen P, Helve T, Koski J, Gripenberg-Gahmberg M, Myllykangas-Luosujärvi R, Leirisalo-Repo M, . FIN-RACo Trial Group (FINish Rheumatoid Arthritis Combination therapy) Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002, 46:894-898. 10.1002/art.10135, 11953964, FIN-RACo Trial Group (FINish Rheumatoid Arthritis Combination therapy).
30. Lard LR, Visser H, Speyer I, vander Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, Hazes JM. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001, 111:446-451. 10.1016/S0002-9343(01)00872-5, 11690569.
31. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004, 350:2591-2602. 10.1056/NEJMra040226, 15201416.
32. Korpela M, Laasonen L, Hannonen P, Kautiainen H, Leirisalo-Repo M, Hakala M, Paimela L, Blåfield H, Puolakka K, Möttönen T. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 2004, 50:2072-2081. 10.1002/art.20351, 15248204.
33. Svensk Reumatologis Kvalitetsregister (SRQ) Available at http://www.srq.nu (accessed 20 April 2014).
34. Ekdahl C, Eberhardt K, Andersson SI, Svensson B. Assessing disability in patients with rheumatoid arthritis: use of a Swedish version of the Stanford Health Assessment Questionnaire. Scand J Rheumatol 1988, 17:263-271. 10.3109/03009748809098795, 3187457.
35. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48. 10.1002/art.1780380107, 7818570.
36. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998, 41:1845-1850. 10.1002/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K, 9778226.
37. Berglin E, Padyukov L, Sundin U, Hallmans G, Stenlund H, Van Venrooij WJ, Klareskog L, Rantapää-Dahlqvist S. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 2004, 6:R303-R308. 10.1186/ar1187, 464874, 15225365.
38. Johansson M, Ärlestig L, Hallmans G, Rantapää-Dahlqvist S. PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease. Arthritis Res Ther 2006, 8:R19. 10.1186/ar1868, 1526580, 16507117.
39. Kokkonen H, Johansson M, Innala L, Jidell E, Rantapaa-Dahlqvist S. The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden. Arthritis Res Ther 2007, 9:R56. 10.1186/ar2214, 2206338, 17553139.
40. Larsen A. How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long-term studies. J Rheumatol 1995, 22:1974-1975.
41. Innala L, Möller B, Ljung L, Magnusson S, Smedby T, Södergren A, Ohman ML, Rantapää-Dahlqvist S, Wållberg-Jonsson S. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther 2011, 13:R131. 10.1186/ar3442, 3239373, 21843325.
42. Turesson C, McClelland RL, Christianson TJ, Matteson EL. Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 2007, 66:70-75. 1798415, 16877533.
43. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990, 300:230-235. 10.1136/bmj.300.6719.230, 1662068, 2106931.
44. Camacho EM, Verstappen SMM, Lunt M, Bunn DK, Symmons DPM. Influence of age and sex on functional outcome over time in a cohort of patients with recent-onset inflammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Care Res (Hoboken) 2011, 63:1745-1752. 10.1002/acr.20609, 22127966.
45. Berglin E, Lorentzon R, Nordmark L, Nilsson-Sojka B, Rantapää-Dahlqvist S. Predictors of radiological progression and changes in hand bone density in early rheumatoid arthritis. Rheumatology (Oxford) 2003, 42:268-275. 10.1093/rheumatology/keg077, 12595621.
46. Kirwan JR, Bijlsma JWJ, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007, 1:CD006356.
47. Hafström I, Albertsson K, Boonen A, van der Heijde D, Landewé R, Svensson B, . BARFOT Study Group Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study. Ann Rheum Dis 2009, 68:508-513. 10.1136/ard.2008.087833, 18420939, BARFOT Study Group.
48. Gorter SL, Bijlsma JW, Cutolo M, Gomez-Reino J, Kouloumas M, Smolen JS, Landewé R. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010, 69:1010-1014. 10.1136/ard.2009.127332, 20448288.
49. Paulus HE, Di Primeo D, Sanda M, Lynch JM, Schwartz BA, Sharp JT, Genant HK, Weissman BN. Progression of radiographic joint erosion during low dose corticosteroid treatment of rheumatoid arthritis. J Rheumatol 2000, 27:1632-1637.
50. Villa-Blanco JI, Calvo-Alén J. Elderly onset rheumatoid arthritis: differential diagnosis and choice of first-line and subsequent therapy. Drugs Aging 2009, 26:739-750. 10.2165/11316740-000000000-00000, 19728748.
51. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000, 43:22-29. 10.1002/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9, 10643696.
52. Tutuncu Z, Kavanaugh A. Rheumatic disease in the elderly: rheumatoid arthritis. Rheum Dis Clin North Am 2007, 33:57-70. 10.1016/j.rdc.2006.12.006, 17367692.
53. Huscher D, Sengler C, Gromnica-Ihle E, Bischoff S, Eidner T, Ochs W, Richter J, Zink A. Clinical presentation, burden of disease and treatment in young-onset and late-onset rheumatoid arthritis: a matched-pairs analysis taking age and disease duration into account. Clin Exp Rheumatol 2013, 31:256-262.
54. Fleischmann RM, Baumgartner SW, Tindall EA, Weaver AL, Moreland LW, Schiff MH, Martin RW, Spencer-Green GT. Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J Rheumatol 2003, 30:691-696.
55. Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, Levin R, Solomon DH. Anti-tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007, 56:1754-1764. 10.1002/art.22600, 17530704.